Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Palvella Therapeutics Inc.

Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
From Palvella Therapeutics Inc.
Via GlobeNewswire
Tickers PVLA
Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025
From Palvella Therapeutics Inc.
Via GlobeNewswire
Tickers PVLA
Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference
From Palvella Therapeutics Inc.
Via GlobeNewswire
Tickers PVLA
Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
From Palvella Therapeutics Inc.
Via GlobeNewswire
Tickers PVLA
Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies
From Palvella Therapeutics Inc.
Via GlobeNewswire
Tickers PVLA
Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
Tickers PVLA
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million
From Palvella Therapeutics Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.